Global formulary review: how do we integrate pharmacogenomic information?

Area of Science:

• Pharmacogenomics (PGx)
• Clinical Pharmacy
• Health Outcomes Research

Background:

• The field of pharmacogenomics (PGx) is rapidly advancing, with increasing evidence supporting genetically guided individualized therapy.
• Integrating PGx data into clinical practice, specifically at the formulary level, requires standardized methods for evaluation and application.
• Existing literature lacks comprehensive guidance on incorporating PGx information into the standard formulary decision-making process.

Purpose of the Study:

• To summarize the standard hospital formulary decision process.
• To provide recommendations for integrating pharmacogenomic (PGx) information into formulary decision-making.
• To bridge the gap between PGx research and its practical application in healthcare settings.

Main Methods:

• A literature search was conducted using MEDLINE and PubMed, combining terms related to hospital formularies, pharmacogenetics, rational drug therapy, and essential medicines lists.
• Relevant articles were assessed, interpreted, and categorized into key areas: formulary management, international formularies, decision-making processes, PGx evidence, and integration strategies.
• The review focused on identifying current practices and challenges in applying PGx data within the formulary context.

Main Results:

• Few standardized methods currently exist for analyzing and applying clinical PGx data for formulary decisions.
• Online resources and specific evaluation questions can aid organizations in incorporating PGx information into drug reviews.
• The integration of PGx data into formulary decisions is essential for optimizing drug efficacy, safety, and cost-effectiveness.

Conclusions:

• Pharmacy and Therapeutics (P&T) committees should develop proactive plans to systematically search for and integrate PGx data during drug evaluations.
• Incorporating PGx information into the formulary decision process can significantly enhance the appraisal of new and existing medications.
• This integration supports the move towards personalized medicine and improved patient outcomes.